BioSpace News Archive

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for expanded indication of the latest iteration of the Indigo® Aspiration System, Lightning™ 12.

In “Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients” researchers provide further proof to the theory that the measles-mumps-rubella (MMR) vaccine provides protection against COVID-19.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has been named one of The Boston Globe’s Top Places to Work in 2020 in the large company category.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020.

Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced the pricing of an underwritten public offering of 14,189,189 shares of its common stock at a price to the public of $0.37 per share.

Matt Monaghan, chairman, president and chief executive officer of Invacare Corporation (NYSE: IVC); Kathleen P. Leneghan, senior vice president and chief financial officer; and Lois Lee, director, treasury, investor relations and corporate communications, will participate in the 32nd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 2, 2020

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors.

Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than 30 million members nationally, recently welcomed three new leaders to transform its information technology and data management and analytics areas.

Today, the Cystic Fibrosis Foundation announced a new research award of up to $3.75 million to Matinas BioPharma for the development of an oral version of amikacin, an antibiotic that targets nontuberculous mycobacteria (NTM) infections in people with cystic fibrosis.

Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been appointed President and Chief Executive Officer